Several positive elements in Eli Lilly Q3 report, says analyst

An analyst at Sydbank thinks that Eli Lilly's third quarter report includes a number of positive elements, and emphasizes that this could also be good news for competitor Novo Nordisk.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

A string of positive results were reported on Tuesday, as US-based Eli Lilly released its financial report for the third quarter of the year. This could also prove good news for its competitor Novo Nordisk, especially when it comes to the sales of its once-weekly GLP-1 drug Ozempic, an analyst from Sydbank assesses.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading